Search

Zealand Pharma A-S

Closed

511.2 1.95

Overview

Share price change

24h

Current

Min

494.9

Max

514.4

Key metrics

By Trading Economics

Income

7.9B

7.6B

Sales

9.1B

9.1B

P/E

Sector Avg

5.498

35.739

EPS

105.61

Profit margin

83.335

Employees

424

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+25.15% upside

Dividends

By Dow Jones

Next Earnings

13 Nov 2025

Market Stats

By TradingEconomics

Market Cap

12B

36B

Previous open

509.25

Previous close

511.2

Zealand Pharma A-S Chart

Past performance is not a reliable indicator of future results.

Related News

1 Oct 2025, 08:54 UTC

Major Market Movers

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

12 Mar 2025, 09:23 UTC

Major Market Movers

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

20 Dec 2024, 09:22 UTC

Major Market Movers

Zealand Pharma Shares Fall After FDA Pushes Back Bowel-Disease Drug

12 Mar 2025, 16:34 UTC

Top News

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12 Mar 2025, 08:18 UTC

Market Talk

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

Zealand Pharma A-S Forecast

Price Target

By TipRanks

25.15% upside

12 Months Forecast

Average 270.582 DKK  25.15%

High 270.568 DKK

Low 270.568 DKK

Based on 1 Wall Street analysts offering 12 month price targets forZealand Pharma A-S - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

0

Buy

1

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
help-icon Live chat